3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
SHANGHAI, March 31, 2026 /PRNewswire/ -- 3SBio Inc. (01530.HK) today released its 2025 annual results announcement. Fueled by the dual core engines of breakthroughs in innovative R&D and strategic global collaboration, the company delivered a...
Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics...
Earendil Labs Announces $787 Million in Financing to Scale AI-Driven Biologics Discovery and Development
WILMINGTON, Del., March 20, 2026 /PRNewswire/ -- Earendil Labs, an AI-driven biotechnology company advancing next-generation biologics, today announced that it has raised $787 million in financing rounds. The investment included participation by a...
Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China
HANGZHOU, China, Feb. 24, 2026 /PRNewswire/ -- Hangzhou Sciwind Biosciences Co., Ltd. ("Sciwind Biosciences") today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation...
Harbour BioMed Announces Positive Profit Alert for 2025 Annual Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 4, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology...
NYSE Content Advisory: Pre-Market Update + AstraZeneca Climbs Nearly 1% After Historic NYSE Transfer
NEW YORK, Feb. 3, 2026 /PRNewswire/ -- The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today's NYSE Pre-market update for market insights before trading begins. NYSE Content...
Fosun Pharma's Subsidiary Yao Pharma and Pfizer Enter into Exclusive Collaboration and License Agreement
SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Fosun Pharma (SSE: 600196; HKEX: 02196) today announced that its subsidiaries, Chongqing Yao Pharmaceutical Company, Limited. ("Yao Pharma"), Shanghai Fosun Pharmaceutical Industrial Development Company...
Nona Biosciences and Pfizer Announce Strategic Research Collaboration to Accelerate Antibody Discovery
Agreement includes license to Nona's fully human HCAb platform for preclinical antibody discovery CAMBRIDGE, Mass., Nov. 19, 2025 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug...
CGTN: How China's high-standard opening up fuels high-quality development
BEIJING, Nov. 9, 2025 /PRNewswire/ -- Following President Xi Jinping's visits to Hainan and Guangdong, CGTN published an article on China's strategic priorities of high-standard opening up to drive high-quality growth. The piece outlines how this...
Pfizer and BioNTech Receive Health Sciences Authority Approval for SARS-CoV-2 Sublineage LP.8.1-Adapted Monovalent COVID-19 Vaccine in Singapore
The updated COVID-19 vaccine is expected to be available in Singapore at selected polyclinics and private general practitioner (GP) clinics in October 2025 for individuals 6 months of age and older. SINGAPORE, Oct. 24, 2025 /PRNewswire/ -- Pfizer...